Company news
Ascelia Pharma Ab (OMXSTO:ACE) news
Ascelia Pharma Ab news releases on 6ix. Latest, Sep 24, 2026: Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic…
Press releases & updates
Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging
September 24, 2026
Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
September 10, 2026
Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026
August 17, 2026
Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base
July 15, 2026
Ascelia Pharma Provides Update on the Orviglance NDA
July 3, 2026
Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing
June 30, 2026
Ascelia Pharma Carries Out a Directed Share Issue of SEK 20 Million
April 23, 2026
Notice of Annual General Meeting in Ascelia Pharma AB
March 30, 2026
Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026
March 27, 2026
Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company
January 21, 2026
Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB
December 22, 2025
Change in Number of Shares and Votes in Ascelia Pharma AB
November 28, 2025
Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program
November 19, 2025
Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review
November 15, 2025
Ascelia Pharma Files New Patent Application for Orviglance
November 10, 2025
Ascelia Pharma Announces Management Changes to Support Future Growth
November 3, 2025
Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration
September 3, 2025
Ascelia Pharma Updates Timeline for Submission of the Orviglance NDA
August 15, 2025
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
May 7, 2025